Suzuki K, Nishioka J, Hashimoto S, Kamiya T, Saito H
Blood. 1983 Dec;62(6):1266-70.
Protein-C inhibitor (PCI) is a newly described plasma inhibitor directed against a vitamin-K-dependent serine protease, activated protein-C, which is involved in the inactivation of factor V and factor VIII. Marlar and Griffin have reported that PCI activity is absent in the plasma of patients with congenital combined factor V/VIII deficiency. We have measured the levels of PCI in the plasma of seven unrelated patients with this disorder using both functional and immunologic methods. The rate at which the amidolytic activity of activated protein-C was neutralized in the patients' plasma was essentially identical to that observed in normal plasma. The titer of PCI antigen, as measured by an electroimmunoassay using a monospecific anti-PCI serum, was 5.3 +/- 1.6 micrograms/ml in the patients' plasma and was not significantly different from that of normal plasma (5.3 +/- 2.7 micrograms/ml, n = 30). The levels of factor-V-related antigen, factor V coagulant antigen, and factor VIII coagulant antigen were low in all patient plasma and were in good agreement with their respective coagulant activity. Our results do not appear to support the hypothesis that combined factor V/VIII defect is due to a lack of PCI.
蛋白C抑制剂(PCI)是一种新发现的血浆抑制剂,作用于维生素K依赖的丝氨酸蛋白酶——活化蛋白C,后者参与因子V和因子VIII的失活过程。马拉尔和格里芬报告称,先天性联合因子V/ VIII缺乏症患者的血浆中不存在PCI活性。我们使用功能学和免疫学方法,测定了7例患有该疾病的非亲属患者血浆中的PCI水平。患者血浆中活化蛋白C的酰胺水解活性被中和的速率,与正常血浆中观察到的速率基本相同。通过使用单特异性抗PCI血清的电免疫测定法测得,患者血浆中PCI抗原的滴度为5.3±1.6微克/毫升,与正常血浆(5.3±2.7微克/毫升,n = 30)无显著差异。所有患者血浆中因子V相关抗原、因子V凝血抗原和因子VIII凝血抗原的水平均较低,且与其各自的凝血活性高度一致。我们的结果似乎不支持联合因子V/ VIII缺陷是由于缺乏PCI这一假说。